Chemotherapy for gastric cancer

Table 4 Phase II studies of preoperative chemotherapy in localized gastric cancer

Author.Year	Number of patients	Neoadjuvant chemotherapy regimen	Adjuvant chemotherapy regimen	R0 rate	PCR	Median survival (mo)	2-yr survival rate (%)
Wilke.1989	34	EAP × 2	EAP × 2	29	5	18	26
Leichman.1992	38	CF ×2	Intraperitoneal	76	3	17	NR
Ajani.1993	48	EAP × 3	EAP × 2	77	0	16	42
Kang.1996	53	EFP ×2-3	EFP × 3-6	71	4	43	NR
	54	Surgery	None	61		30	NR
Crookes.1997	59	CF ×2	Intraperitoneal	71	5	48	64
Songun.1999	27	FAMtx × 4	None	56	0	36	62
	29	Surgery	None	62		13.1	NR

EAP: etoposide, doxorubicin and cisplatin; CF: cisplatin and 5-fluoruracil; EFP: etoposide, 5-fluouracil and cisplatin; FAMtx: 5-fluoruracil, doxorubicin and methotrexate; pCR: pathological complete remission; NR: no reported